Skip to main content

The first and only treatment to show superior efficacy vs standard single-agent chemotherapy in FRα-positive* PROC1-3

*FRα positive is defined as ≥75% of viable tumor cells with moderate (2+) and/or strong (3+) membrane staining based on an IHC assay.4
FRα=folate receptor alpha; IHC=immunohistochemistry; PROC=platinum-resistant ovarian cancer.

 Subgroup Analyses Subgroup Analyses Longer-Term Follow-Up MIRASOL Study Data MIRASOL Study Data Additional Data Patient-Reported Outcomes MIRASOL Study Design Single-Arm Study Data

PFS: EFFICACY OF ELAHERE IN SELECT EXPLORATORY SUBGROUP ANALYSES BY TREATMENT HISTORY2

This study was not powered to evaluate these prespecified subgroups. Data are exploratory and descriptive in nature. No formal inferences can be drawn.2

CI=confidence interval; PARPi=poly(ADP-ribose) polymerase inhibitor; PFS=progression-free survival.

OS: EFFICACY OF ELAHERE IN SELECT EXPLORATORY SUBGROUP ANALYSES BY TREATMENT HISTORY2

This study was not powered to evaluate these prespecified subgroups. Data are exploratory and descriptive in nature. No formal inferences can be drawn.2

OS=overall survival.

ORR: EFFICACY OF ELAHERE IN SELECT EXPLORATORY SUBGROUP ANALYSES BY TREATMENT HISTORY2

This study was not powered to evaluate these prespecified subgroups. Data are exploratory and descriptive in nature. No formal inferences can be drawn.2

ORR population includes 2 patients from each arm that do not appear in the Prescribing Information analysis (patients removed had a CR and PD in the ELAHERE arm and had SD and were NE in the investigator's choice arm).

CR=complete response; NE=not evaluable; ORR=overall response rate; PD=progressive disease; SD=stable disease.

PFS: RESULTS IN A LONGER-TERM FOLLOW-UP5

After the primary analysis data cutoff of March 6, 2023, ELAHERE continued to be studied in patients until September 26, 2024, with a median follow-up of 30.5 months. This represents the updated nonanalytical results from the final data analysis5

Data are exploratory and descriptive in nature. No formal inferences can be drawn.

HR=hazard ratio; mPFS=median progression-free survival.

OS: CONSISTENT RESULTS IN A LONGER-TERM FOLLOW-UP5

After the primary analysis data cutoff of March 6, 2023, ELAHERE continued to be studied in patients until September 26, 2024, with a median follow-up of 30.5 months. This represents the updated nonanalytical results from the final data analysis5

Data are exploratory and descriptive in nature. No formal inferences can be drawn.

mOS=median overall survival.

Need more information
about FRα (FOLR1) testing?

A representative can answer additional questions
you may have about testing for FRα with FOLR1 IHC. REQUEST A REP

Discover more
about dosing

Find comprehensive dosing and administration information,
plus downloadable resources.

GET DOSING DETAILS
  1. ELAHERE. Package insert. AbbVie; 2025.
  2. Moore KN, Angelergues A, Konecny GE, et al. N Engl J Med. 2023;389(23):2162-2174. doi:10.1056/NEJMoa2309169
  3. Matulonis UA, Lorusso D, Oaknin A, et al. J Clin Oncol. 2023;41(13):2436-2445. doi:10.1200/JCO.22.01900
  4. VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. Package insert. Roche; 2022.
  5. Van Gorp T, Angelergues A, Konecny G, et al. Final overall survival analysis among patients with FRα-positive, platinum-resistant ovarian cancer (PROC) treated with mirvetuximab soravtansine (MIRV) vs investigator's choice chemotherapy (ICC) in the phase 3 MIRASOL (GOG 3045/ENGOT-ov55) study. Presented at: Society of Gynecologic Oncology Annual Meeting on Women's Cancer; March 14-17, 2025; Seattle, WA.